Is Daily Nattokinase Safe?

Introduction

In recent years, with increasing attention to cardiovascular health, nattokinase, a natural active ingredient derived from traditional fermented foods, has sparked widespread discussion globally. From health supplement counters in Tokyo to organic supermarkets in New York, from research laboratories to everyday health conversations, the keyword "nattokinase" frequently appears in the health field. However, accompanying its rising popularity is a core question: Is daily nattokinase truly safe?

 

As professionals with years of experience in the field of natural extracts, we understand the confusion consumers face regarding this emerging supplement: Is it suitable for long-term use? Which groups should exercise caution? How to identify high-quality raw materials? This article will systematically analyze the safety framework of nattokinase from three dimensions: scientific mechanisms, clinical research, and usage guidelines, providing professional decision-making references for industry practitioners and end consumers.

 

Nattokinase: An Active Ingredient Beyond Traditional Understanding

 

Nattokinase (NK) is not a marketing concept, but a rigorously defined serine protease produced by *Bacillus subtilis* var. *natto* during soybean fermentation. Its molecular weight is approximately 27.7 kDa, with a specific amino acid sequence and spatial conformation, which endows it with unique fibrinolytic activity.

 

The core of its mechanism of action lies in its "bidirectional regulatory" characteristic: unlike the aggressive approach of traditional thrombolytic drugs, nattokinase exerts its effects through a triple pathway: degrading fibrinogen, activating the endogenous fibrinolytic system, and inhibiting platelet aggregation. Data from the Japan Food Chemistry Research Laboratory (FRL) shows that its activity unit is usually designated as FU (Fibrinolytic Unit), and this standardized measurement provides a quantitative basis for safety assessment.

 

 

It is worth noting that the "natural" nature of nattokinase does not mean absolute safety. As a protein, it must pass through the gastric acid barrier and intestinal transport after oral administration. Differences in stability during this process are key indicators for distinguishing the quality of the raw material. Clinical observations show that enteric coating technology can increase the bioavailability of nattokinase by 40-60%, demonstrating the technological strength of professional suppliers.

 

Dosage Determines Safety: An Evidence-Based Medicine Perspective

Regarding the safety of daily intake, the most authoritative reference comes from the guidelines of the Japan Nattokinase Association (JNKA). Based on data from over 20 human trials, a daily dose range of 2000-4000 FU in healthy adults has been proven to be well-tolerated. A 2019 meta-analysis by the Korean Institute of Food Research further confirmed that within this dose range, continuous use for 6 months did not result in abnormal liver or kidney function or coagulation disorders.

The principle of tiered management for specific populations is crucial:
♦ Level 1 Applicable Population: Individuals aged 45 and above in a sub-healthy state, with a sedentary lifestyle, or borderline elevated blood lipids. 2000 FU daily can be used as a preventative supplement.
♦ Level 2 Caution Population: Individuals currently taking antiplatelet drugs (such as aspirin) or anticoagulants (such as warfarin) should use this product at least 4 hours apart under the supervision of a physician.
♦ Level 3 Contraindications: Patients with bleeding disorders, those recovering from recent surgery, and those with severe cirrhosis and coagulation disorders should avoid use.

The National Institutes of Health (NIH) specifically points out in its dietary supplement database that the safety of nattokinase is positively correlated with its purity. Residual vitamin K2 (a natural component of natto) in the raw materials may interfere with anticoagulation therapy; therefore, K2-free processing is a litmus test for evaluating the technical level of suppliers.

Potential Risks and Hedging Strategies for Long-Term Use

 

For the high-frequency scenario of "daily use," a dynamic risk assessment model needs to be established:

1. Gastrointestinal Adaptability
Approximately 3-5% of initial users may experience bloating or increased flatulence, which is related to nattokinase's promotion of intestinal microcirculation and flora adjustment. A "start-up" strategy is recommended: 1000 FU daily for the first two weeks, gradually increasing to the target dose, which can significantly reduce the incidence of discomfort.

2. Coagulation Function Monitoring
A follow-up study covering 1200 long-term users (Osaka Medical College, 2020) showed that annual PT-INR and APTT tests are sufficient to monitor abnormal risks. For individuals without underlying diseases, the stability rate of coagulation indicators reached 98.7%.

3. Raw Material Traceability Risks
Industry reports indicate that approximately 23% of commercially available products have issues with falsely labeled active units or microbial contamination. This highlights the importance of choosing nattokinase suppliers with HACCP and ISO22000 certifications. Differences in extraction processes can lead to residual natto odor substances (pyrazine compounds) in the product, affecting compliance. Supercritical CO₂ extraction technology can effectively solve this problem.

 

Global Supply Chain Perspective: The Identification Logic of High-Quality Raw Materials

In the natto kinase industry chain, Xi'an Sost Biotech Co., Ltd., a high-tech enterprise with 17 years of experience in the field of plant extracts, has established a complete quality control system from strain screening to end products. Its natto kinase raw material segment demonstrates three core competitive advantages:

In terms of technological barriers, Sost Biotech uses the patented strain SOST-BC-007 to achieve stable enzyme activity expression in a three-stage fermentation system of 30L-500L-5000L. The final product activity can reach 20,000-50,000 FU/g, with a batch-to-batch CV value of <5%. This stability is crucial for the safety of daily consumption-consumers need predictable effects, not the "surprise" of drastic increases or decreases in activity.

In terms of safety management, the company's Agilent 1260 HPLC and real-time quantitative PCR equipment form a triple safety net of "activity detection + gene identification + pathogen screening." Of particular note is its chromatographic process for removing vitamin K2, which reduces the risk of coagulation interference to below 0.8%, the lowest in the industry-a crucial factor for international pharmaceutical clients.

 

Regarding regulatory compliance, Sost Biotech's nattokinase raw material has received affirmative list approval from Japan, GRAS self-certification from the US FDA, and a Novel Food application number from the EU. This multi-country registration capability provides regulatory assurance for the safety of exported products. Its factory, located in the Xi'an National Aviation High-Tech Industrial Base, is cGMP certified, with an annual production capacity of 30 tons, exporting to 38 countries and regions including North America, the EU, Japan, and South Korea, with over 2,000 batches safely exported to date.

 

Practical Advice and Industry Outlook for Consumers

 

For consumers planning to take nattokinase daily, it is recommended to follow the "three checks and three observations" principle:

Three Checks: Check supplier qualifications (ISO/HACCP certification), check activity testing reports (third-party laboratories), check clinical literature support (not just promotional materials).

Three Observations: Observe dosage form design (enteric-coated/acid-resistant), observe excipient list (no redundant additives), observe the authenticity of user feedback.

From an industry development perspective, nattokinase is upgrading from a "single ingredient" to a "synergistic formula." Sost Biotech's R&D center is exploring a combination of nattokinase with quercetin and resveratrol to enhance cardiovascular protection through multi-target intervention while reducing the dosage of single ingredients. This represents a higher level of safety philosophy-using synergy instead of incremental increases.

 

Conclusion
Returning to the core question: Is daily nattokinase safe? The answer is: Under the three premises of strict quality control, scientific dosage range, and clear contraindication screening, long-term daily use has sufficient safety evidence. However, this safety is not automatically achieved; it relies heavily on professional control throughout the entire supply chain, from raw material sourcing to the final product.

 

As an industry player, we firmly believe that true safety stems from transparent information, rigorous science, and responsible production. Xi'an Sost Biotech Co., Ltd. is based on this philosophy, continuously providing global partners with high-quality nattokinase raw materials that withstand regulatory scrutiny and the test of time. Whether you are a brand seeking ODM/OEM services or a dietary supplement manufacturer requiring a stable supply, Sost Biotech's professional team will provide end-to-end solutions, from formulation design to regulatory support.

 

Contact Information:

Email: info@sostherbusa.com

Website: www.sostherb.com

 

References:

Sumi, H. et al. (1990). "A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto." Experientia, 46(10):1110-1111.

Fujita, M. et al. (2011). "Antihypertensive effects of continuous oral administration of nattokinase and its fragments." Journal of Food Biochemistry, 35(3):714-721.

Kim, J.Y. et al. (2019). "Meta-analysis of randomized controlled trials on nattokinase supplementation." Korean Journal of Food Science and Technology, 51(4):389-398.

Japanese Nattokinase Association (2018). Safety Guidelines for Nattokinase Products. Tokyo.